CX Partners-backed Veeda Clinical Research appoints Mahesh Bhalgat as Group CEO

Bhalgat started his India career with Biological E Limited, which he joined after 20 years of pursuing academics and working with multi-national drug development companies in North America. (Representational image)

Private equity firm CX Partners-backed Veeda Clinical Research Limited, one of India's largest independent, full-service clinical research organizations, has named pharma-biotech industry veteran Dr Mahesh Bhalgat as Group CEO.

Prior to joining Veeda, Bhalgat was the COO for Syngene International (Biocon Group Company), India’s largest CRO & CDMO company. Before Syngene, he was the COO and Executive Director for Sanofi in Hyderabad, where he was responsible for initiating the first-ever Indian manufacturing operation for injectable polio vaccine.

Bhalgat started his India career with Biological E Limited, which he joined after 20 years of pursuing academics and working with multi-national drug development companies in North America.

"At Veeda, Dr. Mahesh will provide strategic leadership and drive the integration of different business segments to build a multinational integrated technology-enabled, clinical research organization by overseeing a diverse portfolio of research services of Veeda group companies, which includes Preclinical Research business (Bioneeds India Pvt. Ltd.), and Clinical Research entity (Veeda Clinical Research Limited)," according to an official statement from the firm.

In November 2018, a consortium of private equity investors led by CX Partners acquired a significant equity ownership in Veeda Clinical Research.

Note For Readers: Corporate Crossings is a series from Moneycontrol that will focus the lens on important executive movements within companies and in the industry, and capture the exits and new innings of members of India Inc., investment bankers, lawyers, Big 4 professionals, private equity investors, & more.